Dosage ; Peptic ulcer: 300mg nocte 4/52.
Maintenance: 150mg nocte.
Children over 18 years: 150mg BD.
Not recommended for children below 8yrs.
Zollinger-Ellison syndrome: 150mg TDS up to 6g daily if necessary, in divided doses. Inj. Adults: 50mg by slow 1.V inj or inf. or I.M (repeat six or eight hourly)
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Labtac | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 150mg | 100 | Tablet | per tablet | KES 175.00 |
| Labtac | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 25mg | 1 | Injection | per ml | KES 18.00 |
| Neotack | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 150mg | 150 | Tablet | per tablet | KES 400.00 |
| Neotack | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 50mg | 10 | Injection | per ml | KES 175.00 |
| Ranitidine-Agio | Agio Pharmaceuticals Limited | Pharma Specialities Ltd. | 150mg | 100 | Tablet | per tablet | KES 220.00 |
| Reducid | Flamingo Pharmaceuticals Ltd. | Harley's Limited | 150mg | 100 | Tablet | per tablet | KES 235.00 |
| R-Loc | Zydus Cadila Healthcare | C.Mehta & Co Ltd. | 150mg | 100 | Tablet | per tablet | KES 526 |
| Ultac | Cosmos Limited. | Cosmos Limited | 150mg | 20 | Tablet | per tablet | KES 100.00 |
| Zantac | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 150mg | 100 | Tablet | per tablet | KES 549.00 |
| Zantac | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 300mg | 100 | Tablet | per tablet | KES 549.00 |
| Zantac | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 300mg | 10 | Tablet | per tablet | KES 900.50 |
| Zantac | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 50mg | 5 | Injection | per ml | KES 225.00 |
| Aciloc | Cadila Pharmaceuticals Ltd. | Cadila Pharmaceuticals (EA) | 150mg | 100 | Tablet | per tablet | KES 900.00 |
| Aciloc | Cadila Pharmaceuticals Ltd. | Cadila Pharmaceuticals (EA) | 300mg | 100 | Tablet | per tablet | KES 1,300.00 |
| Aciloc | Cadila Pharmaceuticals Ltd. | Cadila Pharmaceuticals (EA) | 50mg | 5 | Injection | per vial | KES 120.00 |
| Reduced | Flamingo Pharmaceuticals Ltd. | Harley's Limited | 150mg | 100 | Tablet | per tablet | KES 204.00 |
| Neoceptin R | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 150mg | 100 | Tablet | per tablet | KES 549.00 |
| Neoceptin R | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 300mg | 100 | Tablet | per tablet | KES 1,800.00 |
| Ranidin | Acme Laboratories Ltd | Unisel Pharma (K) Ltd. | 50mg | 10 | Injection | per vial | KES 180.00 |
| Rani Denk | Denk Pharma | Laborex Kenya Eurapharma Ltd | 150mg | 20 | Tablet | per tablet | KES 470.59 |
| Ranitin | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 150mg | 100 | Tablet | per tablet | KES 500.00 |
| Ranitin | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 300mg | 100 | Tablet | per tablet | KES 900.00 |
| Ranitin | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 25mg | 5 | Injection | per vial | KES 225.00 |
| Zantac | GlaxoSmithkline | GlaxoSmithKline | 150mg | 20 | Tablet | per tablet | KES 869.60 |
| Zantac | GlaxoSmithkline | GlaxoSmithKline | 300mg | 10 | Tablet | per tablet | KES 766.30 |
| Zantac | GlaxoSmithkline | GlaxoSmithKline | 150mg | 10 | Tablet | per tablet | KES 642.80 |
| Zantac | GlaxoSmithkline | GlaxoSmithKline | 50mg | 5 | Injection | per vial | KES 830.90 |
| Zerocid | Synermed Pharmaceuticals Ltd | Saicare Enterprises Ltd. | 25mg | 5 | Injection | per vial | KES 100.00 |
|
Ranitidine More info |
|
|---|---|
| Mode Of Action | Histamine H2-receptor antagonist |
| Drug Indication | Duodenal ulcers, benign gastric ulcers, and prevention of peptic ulcers associated with NSAIDs, reflux oesophagitis, Zollinger-Ellison syndrome |
| Precautions | No protection against NSAID associated ulceration of the stomach, pregnancy and breast-feeding, exclude possibility of malignancy, porphyria, it does not significantly inhibit hepatic microsomal drug metabolism |
| Contra-Indications | No experience in pregnancy and with children |
| Side Effects | Masking of symptoms of gastric cancer, reversible gynaecomastia (weak anti-androgenic effect), alopecia, hepatic disorders, confusional states, galactorrhoea, blood disorders, loss of libido, acute pancreatitis, GI disturbances, skin rashes, cardiac arrhythmias, hypotension, muscular pain, nephritis, hallucinations. Erythema multiforme, less commonly blurred vision, pancreatitis, involuntary move-ment disorders, interstitial nephritis, alopecia. Masking of symptoms of gastric cancer, reversible |
| Dosage | Peptic ulcer: 300mg nocte 4/52. Maintenance: 150mg nocte. Children over 18 years: 150mg BD. Not recommended for children below 8yrs. Zollinger-Ellison syndrome: 150mg TDS up to 6g daily if necessary, in divided doses. Inj. Adults: 50mg by slow 1.V inj or inf. or I.M (repeat six or eight hourly) |
| Special Information | It is suitable for treatment of pediatric reflux. It is preferred to proton pump inhibitors |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON ALIMENTARY SYSTEM |
| Drug Sub-Category | H-Antagonists
Dosing: Adult Duodenal ulcer: Oral: Treatment: 150 mg twice daily, or 300 mg once daily after the evening meal or at bedtime; maintenance: 150 mg once daily at bedtime Eradication of Helicobacter pylori: Oral: 150 mg twice daily; requires combination therapy Pathological hypersecretory conditions: Oral: 150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 g/day have been used I.V.: Continuous infusion for Zollinger-Ellison: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if >10 mEq or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used Gastric ulcer, benign: Oral: 150 mg twice daily; maintenance: 150 mg once daily at bedtime GERD: Oral: 150 mg twice daily Erosive esophagitis: Oral: Treatment: 150 mg 4 times/day; maintenance: 150 mg twice daily Prevention of heartburn: Oral: Zantac 75® [OTC]: 75 mg 30-60 minutes before eating food or drinking beverages which cause heartburn; maximum: 150 mg in 24 hours; do not use for more than 14 days Patients not able to take oral medication: I.M.: 50 mg every 6-8 hours I.V.: Intermittent bolus or infusion: 50 mg every 6-8 hours Continuous I.V. infusion: 6.25 mg/hour Dosing: Pediatric (For additional information see "Ranitidine: Pediatric drug information") Duodenal and gastric ulcer: Oral: Children 1 month to 16 years: Treatment: 4-8 mg/kg/day divided twice daily; maximum: 300 mg/day Maintenance: 2-4 mg/kg/day once daily; maximum: 150 mg/day I.V.: 2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day GERD and erosive esophagitis: Children 1 month to 16 years: Oral: 5-10 mg/kg/day divided twice daily; maximum: GERD: 300 mg/day, erosive esophagitis: 600 mg/day I.V. (unlabeled): 2-4 mg/kg/day divided every 6-8 hours; maximum: 200 mg/day or as an alternative Continuous infusion: Initial: 1 mg/kg/dose for one dose followed by infusion of 0.08-0.17 mg/kg/hour or 2-4 mg/kg/day Prevention of heartburn: Oral: Children ≥12 years: Zantac 75® [OTC]: 75 mg 30-60 minutes before eating food or drinking beverages which cause heartburn; maximum: 150 mg/24 hours; do not use for more than 14 days Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment Adults: Clcr <50 mL/minute: Oral: 150 mg every 24 hours; adjust dose cautiously if needed I.V.: 50 mg every 18-24 hours; adjust dose cautiously if needed Hemodialysis: Adjust dosing schedule so that dose coincides with the end of hemodialysis. Dosing: Hepatic Impairment Patients with hepatic impairment may have minor changes in ranitidine half-life, distribution, clearance, and bioavailability; dosing adjustments are not necessary; monitor patient |